News & Blog
News & Blog
Larimar Therapeutics Announces $95 Million Private Placement Financing
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
Meet The Community: Emily Young
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
Meet The Community: Indiamara Zanandréa
Meet The Community: Megan Sonja Clegg
Meet The Community: Amanda Oliver
Meet The Community: Maria Sobotka
Meet The Community: Dr. Georg Herdt
